SEC Tracker
Get the app

Liminatus Pharma LIMN

Liminatus Pharma Q3 FY25: net loss $1.8M; diluted EPS −$0.07

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Liminatus Pharma reported for Q3 FY25, the quarter ended Sep 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$1.8MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Diluted EPS−$0.07No year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$725KNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$601KNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Liminatus Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Precigen PGEN public float $219M, Jun 30, 2025
  2. SELLAS Life Sciences Group SLS public float $219M, Jun 30, 2025
  3. Lifecore Biomedical LFCR public float $223M, Jun 30, 2025
  4. Sagimet Biosciences SGMT public float $228M, Jun 30, 2025
  5. Perspective Therapeutics CATX public float $213M, Jun 30, 2025